PHARMARON(SZ:300759)2024-08-28 08:47Financial Performance - The company achieved operating revenue of 5.604 billion yuan, a slight decrease of 0.63% compared to the same period last year [2] - Net profit attributable to shareholders was 1.113 billion yuan, an increase of 41.64% year-on-year [2] - Adjusted net profit under non-IFRS was 690 million yuan, a decrease of 25.93% year-on-year [2] Business Growth - New signed orders increased by over 15% year-on-year, with more than 2,200 global clients served and over 360 new clients added [3] - Revenue from clients in North America accounted for 65.45%, Europe (including the UK) 16.87%, China 15.03%, and other regions 2.65% [3] Segment Performance - Laboratory Services: Revenue of 3.371 billion yuan, a decrease of 0.27%, with a gross margin of 44.46% [3] - CMC (Small Molecule CDMO) Services: Revenue of 1.176 billion yuan, a decrease of 6.04%, with a gross margin of 28.30% [3] - Clinical Research Services: Revenue of 843 million yuan, an increase of 4.73%, with a gross margin of 12.55% [3] - Large Molecule and Cell & Gene Therapy Services: Revenue of 211 million yuan, an increase of 5.49%, with a gross margin of -31.34% [3] Strategic Insights - The company anticipates a steady increase in demand from top 20 pharmaceutical companies, with expectations of further revenue growth as CMC projects are delivered [4] - The company is actively planning for capacity expansion in Shaoxing to meet growth demands [4] - The company aims to achieve positive free cash flow with a capital expenditure of 950 million yuan in the first half of 2024, slightly lower than the previous year's 2.8 billion yuan [5]